Australia is eagerly awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://sachingyys172473.xzblogs.com/83188728/this-new-drug-retatrutide-australia-a-potential-hope-for-weight-management